We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why You Should Keep Ingevity (NGVT) Stock in Your Portfolio
Read MoreHide Full Article
Ingevity Corporation (NGVT - Free Report) is expected to gain from its cost-saving actions, the acquisition of the Capa caprolactone business and growth in its applications driven by regulations and technology adoption amid demand weakness in certain businesses.
Shares of this specialty chemicals and materials maker are down 34.5% year to date, compared with the 9.2% decline of its industry.
Let’s find out why this Zacks Rank #3 (Hold) stock is worth retaining at the moment.
What’s Favoring the Stock?
Ingevity is benefiting from higher sales in China as automakers in the country have essentially completed the implementation of the China 6 standard. It saw higher demand for its automotive activated carbon products in China in the second quarter of 2020 on the back of the China 6 implementation. The momentum is expected to continue in the third quarter.
Moreover, Ingevity is seeing healthy growth in pavement technologies on strength in North America. It is seeing continued adoption of the Evotherm warm-mix technology.
The company is also taking certain cost-reduction measures in the wake of the coronavirus pandemic to boost profitability. These actions include reduction of headcount through an early retirement program, streamlining of manufacturing processes and reduction of traveling expenses and plant spending. Ingevity saw benefits of these initiatives in the second quarter. The company expects these actions to deliver $35 million of savings this year.
Ingevity is also gaining from the acquisition of the Capa caprolactone business. Capa has a strong and market-leading business that focuses on high-growth end-use applications. The buyout enabled Ingevity with a new technology platform to drive revenue and earnings growth.
A Few Headwinds
Ingevity faces softness in industrial specialties applications. In the second quarter, its Performance Chemicals unit was affected by lower demand in industrial specialties applications including printing inks. The company witnessed a roughly 24% decline in sales related to industrial specialties applications in the quarter, hurt by weak demand in industrial markets due to the impacts of the pandemic as well as the exit of an unprofitable distribution deal. Pressure in industrial specialties is likely to continue going forward.
The company is also exposed to challenges from lower sales to oilfield technology customers. Sales from its oilfield technologies business tumbled around 52% in the second quarter on lower drilling and production in North America. Drilling and production have been impacted by a global glut of inventory. Weakness in oilfield technologies is likely to continue moving ahead amid lower demand.
Better-ranked stocks stocks worth considering in the basic materials space include AngloGold Ashanti Limited (AU - Free Report) , Barrick Gold Corporation (GOLD - Free Report) and Eldorado Gold Corporation (EGO - Free Report) .
AngloGold Ashanti has a projected earnings growth rate of 124.2% for the current year. The company’s shares have shot up roughly 56% in a year. It currently sports a Zacks Rank #1 (Strong Buy).
Barrick Gold has a projected earnings growth rate of 80.4% for the current year. The company’s shares have rallied around 75% in a year. It currently has a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Eldorado Gold has an expected earnings growth rate of 2,325% for the current year. The company’s shares have gained around 33% in the past year. It currently carries a Zacks Rank #2 (Buy).
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Why You Should Keep Ingevity (NGVT) Stock in Your Portfolio
Ingevity Corporation (NGVT - Free Report) is expected to gain from its cost-saving actions, the acquisition of the Capa caprolactone business and growth in its applications driven by regulations and technology adoption amid demand weakness in certain businesses.
Shares of this specialty chemicals and materials maker are down 34.5% year to date, compared with the 9.2% decline of its industry.
Let’s find out why this Zacks Rank #3 (Hold) stock is worth retaining at the moment.
What’s Favoring the Stock?
Ingevity is benefiting from higher sales in China as automakers in the country have essentially completed the implementation of the China 6 standard. It saw higher demand for its automotive activated carbon products in China in the second quarter of 2020 on the back of the China 6 implementation. The momentum is expected to continue in the third quarter.
Moreover, Ingevity is seeing healthy growth in pavement technologies on strength in North America. It is seeing continued adoption of the Evotherm warm-mix technology.
The company is also taking certain cost-reduction measures in the wake of the coronavirus pandemic to boost profitability. These actions include reduction of headcount through an early retirement program, streamlining of manufacturing processes and reduction of traveling expenses and plant spending. Ingevity saw benefits of these initiatives in the second quarter. The company expects these actions to deliver $35 million of savings this year.
Ingevity is also gaining from the acquisition of the Capa caprolactone business. Capa has a strong and market-leading business that focuses on high-growth end-use applications. The buyout enabled Ingevity with a new technology platform to drive revenue and earnings growth.
A Few Headwinds
Ingevity faces softness in industrial specialties applications. In the second quarter, its Performance Chemicals unit was affected by lower demand in industrial specialties applications including printing inks. The company witnessed a roughly 24% decline in sales related to industrial specialties applications in the quarter, hurt by weak demand in industrial markets due to the impacts of the pandemic as well as the exit of an unprofitable distribution deal. Pressure in industrial specialties is likely to continue going forward.
The company is also exposed to challenges from lower sales to oilfield technology customers. Sales from its oilfield technologies business tumbled around 52% in the second quarter on lower drilling and production in North America. Drilling and production have been impacted by a global glut of inventory. Weakness in oilfield technologies is likely to continue moving ahead amid lower demand.
Ingevity Corporation Price and Consensus
Ingevity Corporation price-consensus-chart | Ingevity Corporation Quote
Stocks to Consider
Better-ranked stocks stocks worth considering in the basic materials space include AngloGold Ashanti Limited (AU - Free Report) , Barrick Gold Corporation (GOLD - Free Report) and Eldorado Gold Corporation (EGO - Free Report) .
AngloGold Ashanti has a projected earnings growth rate of 124.2% for the current year. The company’s shares have shot up roughly 56% in a year. It currently sports a Zacks Rank #1 (Strong Buy).
Barrick Gold has a projected earnings growth rate of 80.4% for the current year. The company’s shares have rallied around 75% in a year. It currently has a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Eldorado Gold has an expected earnings growth rate of 2,325% for the current year. The company’s shares have gained around 33% in the past year. It currently carries a Zacks Rank #2 (Buy).
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>